Top-News

Indivior ADR News

Aktie
WKN:  A12GT3 ISIN:  US45579E1055 US-Symbol:  INVVY
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
146,01 Mio.
Marktkapitalisierung *
-
Streubesitz
-
Faktor
0.2
Originalaktie
GB00BN4HT335
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 11.04.2019

Indivior ADR News

25.04.24 - PR Newswire
Indivior Announces Q1 2024 Financial Results
Indivior Announces Q1 2024 Financial Results PR Newswire
25.04.24 - PR Newswire
Indivior Announces Q1 2024 Financial Results
Indivior Announces Q1 2024 Financial Results PR Newswire
11.03.24 - PR Newswire
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-​Induced Respiratory Depression in Head-​to-Head Study ...
29.02.24 - PR Newswire
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation PR ...
22.02.24 - PR Newswire
Indivior Announces Q4 / FY 2023 Financial Results
Indivior Announces Q4 / FY 2023 Financial Results PR Newswire
22.02.24 - PR Newswire
Indivior Announces Q4 / FY 2023 Financial Results
Indivior Announces Q4 / FY 2023 Financial Results PR Newswire
09.11.23 - PR Newswire
Indivior Announces Q3 2023 Financial Results
Indivior Announces Q3 2023 Financial Results PR Newswire
09.11.23 - PR Newswire
Indivior Announces Q3 2023 Financial Results
Indivior Announces Q3 2023 Financial Results PR Newswire
11.10.23 - PR Newswire
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals PR Newswire
26.09.23 - PR Newswire
Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada
Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada PR Newswire
21.08.23 - PR Newswire
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-​District Litigation Claims PR Newswire
21.08.23 - PR Newswire
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-​District Litigation Claims PR Newswire
27.07.23 - PR Newswire
Indivior Announces Q2/H1 2023 Financial Results
Indivior Announces Q2/H1 2023 Financial Results PR Newswire
27.07.23 - PR Newswire
Indivior Announces Q2/H1 2023 Financial Results
Indivior Announces Q2/H1 2023 Financial Results PR Newswire
14.06.23 - PR Newswire
Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence
Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence PR Newswire
12.06.23 - PR Newswire
Indivior to Commence Trading on Nasdaq
Indivior to Commence Trading on Nasdaq PR Newswire
02.06.23 - PR Newswire
Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims
Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-​District Litigation Claims PR Newswire
02.06.23 - PR Newswire
Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims
Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-​District Litigation Claims PR Newswire
25.05.23 - PR Newswire
Indivior To Participate In Upcoming Investor Conferences
Indivior To Participate In Upcoming Investor Conferences PR Newswire
23.05.23 - PR Newswire
Indivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th
Indivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th PR Newswire

Newssuche

Videos

newspaper
07.05.24 +6,80%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »